ATE196548T1 - Auswählen von agonisten und antagonisten von liganden - Google Patents

Auswählen von agonisten und antagonisten von liganden

Info

Publication number
ATE196548T1
ATE196548T1 AT92912746T AT92912746T ATE196548T1 AT E196548 T1 ATE196548 T1 AT E196548T1 AT 92912746 T AT92912746 T AT 92912746T AT 92912746 T AT92912746 T AT 92912746T AT E196548 T1 ATE196548 T1 AT E196548T1
Authority
AT
Austria
Prior art keywords
ligands
receptor
antagonists
hormone
novel
Prior art date
Application number
AT92912746T
Other languages
English (en)
Inventor
Brian C Cunningham
Abraham M Devos
Michael G Mulkerrin
Mark Ultsch
James Wells
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE196548T1 publication Critical patent/ATE196548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/61—Growth hormones [GH] (Somatotropin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
AT92912746T 1991-05-10 1992-05-06 Auswählen von agonisten und antagonisten von liganden ATE196548T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69875391A 1991-05-10 1991-05-10
US86412092A 1992-04-06 1992-04-06
PCT/US1992/003743 WO1992021029A1 (en) 1991-05-10 1992-05-06 Selecting ligand agonists and antagonists

Publications (1)

Publication Number Publication Date
ATE196548T1 true ATE196548T1 (de) 2000-10-15

Family

ID=27106277

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912746T ATE196548T1 (de) 1991-05-10 1992-05-06 Auswählen von agonisten und antagonisten von liganden

Country Status (6)

Country Link
US (3) US5506107A (de)
EP (1) EP0586549B1 (de)
JP (3) JP3417558B2 (de)
AT (1) ATE196548T1 (de)
DE (1) DE69231467T2 (de)
WO (1) WO1992021029A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6429186B1 (en) 1991-05-10 2002-08-06 Genentech, Inc. Ligand antagonists for treatment of breast cancer
EP0586549B1 (de) * 1991-05-10 2000-09-20 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
DE69329247T2 (de) * 1992-06-09 2001-05-31 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Kristallisierung von m-csf
US5686268A (en) 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
WO1994002611A2 (en) * 1992-07-28 1994-02-03 New England Deaconess Hospital Recombinant human erythropoietin with altered biological activity
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
EP0672144A1 (de) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6-receptor-antagonisten
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
JP3983280B2 (ja) * 1993-02-19 2007-09-26 ジェネンテック・インコーポレーテッド 乳ガンの治療のためのリガンドアンタゴニスト
US5789552A (en) * 1993-06-23 1998-08-04 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
AU6163196A (en) * 1995-06-07 1996-12-30 Smithkline Beecham Corporation Method for obtaining receptor agonist antibodies
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
ES2190388T3 (es) * 1995-09-21 2006-04-01 Genentech, Inc. Variantes de la hormona de crecimiento humana.
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6103879A (en) * 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
WO1997048729A1 (en) * 1996-06-21 1997-12-24 Arris Pharmaceutical Corporation Bivalent molecules that form an activating complex with an erythropoietin receptor
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
SE9701010D0 (sv) * 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6639050B1 (en) 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6570062B1 (en) * 1997-07-21 2003-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB9723955D0 (en) * 1997-11-14 1998-01-07 Generic Biolog Limited Improvements in or relating to detection of molecules in samples
EP1079230B1 (de) * 1998-04-14 2005-08-10 Chugai Seiyaku Kabushiki Kaisha Verfahren zum screenen einer die oligomerisierung von rezeptorproteinmolekülen fördernden substanz
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
CN1326880C (zh) * 1998-04-30 2007-07-18 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
ATE366114T1 (de) 1998-05-12 2007-07-15 Greenville Hospital System Verwendung von anti-prolaktin agentien zur behandlung von krebs
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6946265B1 (en) * 1999-05-12 2005-09-20 Xencor, Inc. Nucleic acids and proteins with growth hormone activity
US6585995B1 (en) 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
US20020032154A1 (en) * 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
EP1290170A2 (de) * 2000-06-16 2003-03-12 Asterion Limited Bindungsreagenzien: chimäre ligand/rezeptorproteine
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
DK1642910T3 (da) 2000-12-05 2012-05-07 Alexion Pharma Inc Rationelt designede atistoffer
US6858148B2 (en) * 2003-07-16 2005-02-22 The Regents Of The University Of California Method and apparatus for detecting chemical binding
CA2450473C (en) 2001-06-14 2011-11-15 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
JP4444652B2 (ja) 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
JP3993560B2 (ja) * 2001-08-30 2007-10-17 ステム セル セラピューティクス インコーポレイテッド 神経幹細胞の分化およびその治療用途
CA2460184A1 (en) * 2001-09-14 2003-03-27 Stem Cell Therapeutics Inc. Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
GB2389115B (en) * 2001-12-14 2005-03-16 Asterion Ltd Polypeptide having a plurality of modified growth hormone receptor binding domains of growth hormone
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20040209801A1 (en) 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
EP1572106B1 (de) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
TWI364295B (en) * 2002-12-26 2012-05-21 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
DE10306992A1 (de) * 2003-02-19 2005-08-11 Klinikum der Universität München Großhadern-Innenstadt Verfahren zur quantitativen Messung von Liganden in der Probe gelöster Bindungsproteine
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
DE20311760U1 (de) * 2003-07-30 2003-12-11 Trw Automotive Safety Systems Gmbh Fahrzeuglenkrad
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US20060026719A1 (en) * 2004-01-14 2006-02-02 Kieliszewski Marcia J Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
JP4896745B2 (ja) * 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
US7846898B2 (en) * 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
EP1751177A4 (de) 2004-04-19 2008-07-16 Univ Ohio Vernetzbare glycoproteine und verfahren zu ihrer herstellung
CA2567813C (en) 2004-05-23 2015-11-24 Gerard M. Housey Theramutein modulators
EP1771066A2 (de) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodellierung von verzweigtem peg und klykolysierung von glucagonähnlichem peptide-1 glp-1
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
AU2005291810B2 (en) 2004-10-07 2011-12-08 Stem Cell Therapeutics Corp. Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds
EP1805216A2 (de) * 2004-10-18 2007-07-11 Novo Nordisk A/S Wachstumshormonkonjugate
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
US8080391B2 (en) * 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
MX2007007580A (es) * 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
JP5137821B2 (ja) 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
EP2422615B1 (de) 2005-07-29 2014-06-18 Targeted Growth, Inc. Dominant-negative KRP-Proteinmutante als Schutz gegen die Hemmung von aktivem Cyclin-CDK-Komplex durch Wildtyp-KRP
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
US7723112B2 (en) * 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2009514535A (ja) * 2005-11-03 2009-04-09 レッドポイント バイオ コーポレイション Ｔｒｐｍ５イオンチャネルのためのハイスループットスクリーニングアッセイ
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN103789389B (zh) 2005-11-23 2017-01-04 杰勒德·M·豪斯 鉴定、合成、优化和表征蛋白调节剂的化合物和方法
WO2007062213A2 (en) 2005-11-23 2007-05-31 Housey Pharmaceuticals Inc Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators
WO2007094916A2 (en) * 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
JP2009530234A (ja) * 2006-03-17 2009-08-27 ステム セル セラピューティクス コーポレイション 神経変性疾患の治療のためのｌｈまたはｈｃｇ、およびｅｐｏについての投与レジメン
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008013861A2 (en) * 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US7748445B2 (en) * 2007-03-02 2010-07-06 National Oilwell Varco, L.P. Top drive with shaft seal isolation
DK2144923T3 (da) 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US7875452B2 (en) * 2007-10-01 2011-01-25 Redpoint Bio Corporation Non-desensitizing mutant of the transient receptor potential TRPM5 ion channel
CA2715465C (en) 2008-02-27 2017-03-21 Novo Nordisk A/S Conjugated factor viii molecules
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP2741760A2 (de) 2011-08-12 2014-06-18 B.S.R.C. "Alexander Fleming" Trimerisierungsinhibitoren der tnf-superfamilie
DK2790687T3 (en) 2011-12-16 2018-11-19 Poseida Therapeutics Inc TRPC4 MODULATORS FOR USE IN TREATMENT OR PREVENTION OF Pain
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59690A (en) * 1980-03-24 1983-11-30 Yeda Res & Dev Production of bovine growth hormone by microorganisms and modified microorganisms adapted to produce it
EP0103395A3 (de) * 1982-08-17 1985-05-22 Biogen N.V. DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von rinderwachstumshormonähnlichen Polypeptiden, mit grosser Ausbeute
BG49718A3 (en) * 1983-07-15 1992-01-15 Bio- Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
DE3588249T2 (de) * 1984-08-16 2004-05-06 Savient Pharmaceuticals, Inc. Methode zur Herstellung von menschlichen Wachstumshormonen
US4782139A (en) * 1985-10-28 1988-11-01 Eli Lilly And Company Selective chemical removal of a protein amino-terminal residue
US4857637A (en) 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
JPH01502640A (ja) * 1987-03-12 1989-09-14 アムジエン・インコーポレーテツド ウシ成長ホルモン類似体
ZA891588B (en) * 1988-03-07 1990-11-28 Lilly Co Eli Phenethanolamine and growth hormone combinations
US4936849A (en) 1988-03-15 1990-06-26 Minnesota Mining And Manufacturing Company Intraocular lens
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
DE68929151T2 (de) * 1988-10-28 2000-07-20 Genentech, Inc. Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
EP0441889A1 (de) * 1988-11-07 1991-08-21 Commission des Communautés Européennes Modifiziertes menschliches wachstumshormon
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
WO1991002754A1 (en) * 1989-08-22 1991-03-07 Immunex Corporation Fusion proteins comprising gm-csf and il-3
WO1991005853A1 (en) * 1989-10-12 1991-05-02 Ohio University Growth hormone antagonists
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5650554A (en) 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
CA2102129C (en) * 1991-05-01 2003-04-01 John J. Kopchick Growth hormone antagonists
EP0586549B1 (de) * 1991-05-10 2000-09-20 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
WO1993000109A1 (en) 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US6238915B1 (en) 1996-02-13 2001-05-29 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses

Also Published As

Publication number Publication date
US6800740B1 (en) 2004-10-05
JP2003159061A (ja) 2003-06-03
JP2001270837A (ja) 2001-10-02
US5506107A (en) 1996-04-09
DE69231467T2 (de) 2001-01-25
JP3417558B2 (ja) 2003-06-16
EP0586549B1 (de) 2000-09-20
US6936440B1 (en) 2005-08-30
JPH06507715A (ja) 1994-09-01
DE69231467D1 (de) 2000-10-26
JP3572263B2 (ja) 2004-09-29
EP0586549A1 (de) 1994-03-16
WO1992021029A1 (en) 1992-11-26

Similar Documents

Publication Publication Date Title
ATE196548T1 (de) Auswählen von agonisten und antagonisten von liganden
LESNIAK et al. Human growth hormone radioreceptor assay using cultured human lymphocytes
Ehrlich et al. Mixing two monoclonal antibodies yields enhanced affinity for antigen.
Blundell et al. X-ray analysis and the structure of insulin
SOAMES et al. Interactions between human complement components factor H, factor I and C3b
DE69229911D1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen
ATE344279T1 (de) Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
EA200301117A1 (ru) Антитела против vla-1
ATE88277T1 (de) Gegen eine substanz mit niedrigem molekulargewicht spezifischer antikoerper und verfahren zu seiner herstellung mittels kolloidaler metallteilchen als traeger.
Krichevsky et al. Preparation and characterization of antibodies to the urinary fragment of the human chorionic gonadotropin β-subunit
Saluk et al. The unique molecular weight of the heavy chain from human IgG3
Mardiney Jr et al. Ultrastructural localization of the third and fourth components of complement on complement-cell complexes.
DE69115917D1 (de) Humane gammainterferonantagonisten
DK0684835T3 (da) Ligandantagonister til behandling af brystcancer
DE3751182D1 (de) Monoklonale Antikörper, B-spezifisch für Apolipoprotein, die von zwei Hybridomen erzeugt werden.
Moyle et al. Detection of conformational changes in human chorionic gonadotropin upon binding to rat gonadal receptors.
Margossian et al. Influence of the cardiac myosin hinge region on contractile activity.
Baran et al. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.
Venkatesh et al. Dissociation of monoclonal antibody-antigen complexes: implications for ELISA procedures
Møller et al. Fc-mediated immune precipitation. III. Visualization by electron microscopy.
ATE188248T1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
Mansour et al. Multiple opioid receptor subtypes in the pituitary-adrenal axis: a cross-species study.
BELL et al. Iodinated FSH: Components and their properties
Podder et al. 2-(1-Naphthylmethyl)-2-imidazoline hydrochloride (naphazoline hydrochloride), C14H15N2+. Cl−, an α-adrenergic agonist
Whitla et al. The crystal structure of [PtCl (OMe)(dicyclopentadiene)]

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification